Inflammatory burden index predicts long-term mortality: evidence from population-based cohorts with clinical validation
4 affiliations
- 1Department of Hospital Infection Management, China-Japan Union Hospital of Jilin University
- 2Meihe Health Research Institute, The First Hospital of Jilin University
- 3Department of Epidemiology and Biostatistics, School of Public Health, Jilin University
- 4Division of Clinical Epidemiology, The First Hospital of Jilin University
Abstract
Background: Systemic inflammation is increasingly recognized as a key determinant of long-term health outcomes. The Inflammatory Burden Index (IBI), derived from C-reactive protein, neutrophil count, and lymphocyte count, integrates multiple components of systemic inflammatory and immune status. However, evidence regarding its association with long-term mortality among individuals with and without a history of cancer remains limited.
Methods: We investigated the associations of IBI with mortality outcomes using two population-based cohorts, the UK Biobank (UKB) and the National Health and Nutrition Examination Survey (NHANES, 1999–2010), and an independent clinical cohort of patients with gastric cancer. Multivariable Cox proportional hazards models were used to evaluate the associations between IBI and mortality outcomes. Stratified analyses were performed by history of cancer and among participants with digestive tract cancers, and sensitivity analyses were conducted to assess robustness.
Results: The UKB included 455,423 participants, of whom 54,813 had a history of cancer, and NHANES included 24,708 participants, of whom 2,159 had a history of cancer. Participants with a history of cancer were more frequently represented in the highest IBI quartile in both cohorts. Higher IBI was consistently associated with increased all-cause, cancer-specific, and CVD-specific mortality. In the UKB, among participants with a history of cancer, the highest versus lowest IBI quartile was associated with higher risks of all-cause (HR = 1.62, 95% CI: 1.53–1.71), cancer-specific (HR = 1.55, 95% CI: 1.45–1.64), and CVD-specific mortality (HR = 1.81, 95% CI: 1.41–2.33). Consistent associations were observed in NHANES and remained robust in continuous and sensitivity analyses. Among participants with digestive tract cancers, higher IBI was associated with increased all-cause and cancer-specific mortality. In the independent gastric cancer cohort (n = 793), the highest IBI quartile was associated with poorer overall survival after multivariable adjustment (HR = 2.53, 95% CI: 1.59–4.02).
Conclusion: Higher IBI was consistently associated with increased all-cause, cancer-specific, and CVD-specific mortality across population-based cohorts, with additional evidence from participants with digestive tract cancers and an independent gastric cancer cohort. These findings support the potential prognostic relevance of IBI as a readily accessible marker of systemic inflammatory burden.
Related
- Development and validation of a novel metabolic-inflammatory health-related nomogram for predicting in-hospital mortality in older patients with type 2 diabetes mellitus combined with cardiovascular disease
- Inflammatory and immune-nutritional indices as prognostic markers of mortality after cardiac procedures: evidence from MIMIC-IV.
- Limited incremental value of three complete-blood-count inflammatory indices for cardiovascular mortality: a development and external validation study in 30,533 US adults
- Isoquercetin Attenuates Graves’ Disease-Related Thyroid Epithelial Inflammatory Responses: Exploratory Evidence from Network Pharmacology, Mendelian Randomization, and Cellular Validation
- Development and validation of a competing-risk nomogram for predicting cancer-specific mortality in prostate cancer: a SEER population-based study
BibTeX
@article{zhang2026inflammatory,
title = {{Inflammatory burden index predicts long-term mortality: evidence from population-based cohorts with clinical validation}},
author = {Yuzheng Zhang and Xinyi Yu and Zhifang Jia and Shuo Yang and Wanying Huo and Chenhao Fu and Jing Jiang},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1932811},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1932811/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Inflammatory burden index predicts long-term mortality: evidence from population-based cohorts with clinical validation
AU - Yuzheng Zhang
AU - Xinyi Yu
AU - Zhifang Jia
AU - Shuo Yang
AU - Wanying Huo
AU - Chenhao Fu
AU - Jing Jiang
PY - 2026
DA - 2026/10/15
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1932811
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1932811/full
AB - Background: Systemic inflammation is increasingly recognized as a key determinant of long-term health outcomes. The Inflammatory Burden Index (IBI), derived from C-reactive protein, neutrophil count, and lymphocyte count, integrates multiple components of systemic inflammatory and immune status. However, evidence regarding its association with long-term mortality among individuals with and without a history of cancer remains limited. Methods: We investigated the associations of IBI with mortality outcomes using two population-based cohorts, the UK Biobank (UKB) and the National Health and Nutrition Examination Survey (NHANES, 1999–2010), and an independent clinical cohort of patients with gastric cancer. Multivariable Cox proportional hazards models were used to evaluate the associations between IBI and mortality outcomes. Stratified analyses were performed by history of cancer and among participants with digestive tract cancers, and sensitivity analyses were conducted to assess robustness. Results: The UKB included 455,423 participants, of whom 54,813 had a history of cancer, and NHANES included 24,708 participants, of whom 2,159 had a history of cancer. Participants with a history of cancer were more frequently represented in the highest IBI quartile in both cohorts. Higher IBI was consistently associated with increased all-cause, cancer-specific, and CVD-specific mortality. In the UKB, among participants with a history of cancer, the highest versus lowest IBI quartile was associated with higher risks of all-cause (HR = 1.62, 95% CI: 1.53–1.71), cancer-specific (HR = 1.55, 95% CI: 1.45–1.64), and CVD-specific mortality (HR = 1.81, 95% CI: 1.41–2.33). Consistent associations were observed in NHANES and remained robust in continuous and sensitivity analyses. Among participants with digestive tract cancers, higher IBI was associated with increased all-cause and cancer-specific mortality. In the independent gastric cancer cohort (n = 793), the highest IBI quartile was associated with poorer overall survival after multivariable adjustment (HR = 2.53, 95% CI: 1.59–4.02). Conclusion: Higher IBI was consistently associated with increased all-cause, cancer-specific, and CVD-specific mortality across population-based cohorts, with additional evidence from participants with digestive tract cancers and an independent gastric cancer cohort. These findings support the potential prognostic relevance of IBI as a readily accessible marker of systemic inflammatory burden.
SN - 2234-943X
ER -